remote hemodynamic monitoring
Recently Published Documents


TOTAL DOCUMENTS

8
(FIVE YEARS 2)

H-INDEX

1
(FIVE YEARS 1)

2021 ◽  
Author(s):  
Sumant P Radhoe ◽  
Jasper J Brugts

Remote monitoring is becoming increasingly important for management of chronic heart failure patients. Recently, hemodynamic monitoring by measuring intracardiac filling pressures has been gaining attention. It is believed that hemodynamic congestion precedes clinical congestion by several weeks and that remote hemodynamic monitoring therefore enables clinicians to intervene in an early stage and prevent heart failure hospitalizations. The CardioMEMS HF system (Abbott, CA, USA) is a sensor capable of measuring pulmonary artery pressures as a surrogate of left ventricular filling pressures. Clinical evidence for CardioMEMS has been convincing in terms of efficacy and safety. This article provides detailed information on the CardioMEMS HF system and summarizes all available evidence of this promising technique.


F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 2134 ◽  
Author(s):  
Leo F Buckley ◽  
Amil M Shah

After more than a decade of relatively modest advancements, heart failure therapeutic development has accelerated, with the PARADIGM-HF trial and the SHIFT trial demonstrated significant reductions in cardiovascular death and heart failure hospitalization for sacubitril-valsartan and in heart failure hospitalization alone for ivabradine. Several heart failure therapies have since received or stand on the verge of market approval and promise substantive advances in the treatment of chronic heart failure. Some of these improve clinical outcomes, whereas others improve functional or patient-reported outcomes. In light of these rapid advances in the care of adults living with chronic heart failure, in this review we seek to update the general practitioner on novel heart failure therapies. Specifically, we will review recent data on the implementation of sacubitril-valsartan, treatment of functional mitral regurgitation, sodium-glucose co-transporter-2 (SGLT-2) inhibitor therapy, agents for transthyretin amyloid cardiomyopathy, treatment of iron deficiency in heart failure, and the use of biomarkers or remote hemodynamic monitoring to guide heart failure therapy.


2017 ◽  
Vol 23 (8) ◽  
pp. S108
Author(s):  
Udit B. Bhatnagar ◽  
Michelle Corothers ◽  
Paul Thompson ◽  
Orvar Jonsson

2016 ◽  
Author(s):  
Bennet George ◽  
Amanda Hart ◽  
Sarah Branam ◽  
Maya Guglin

Remote intracardiac hemodynamic monitoring is a growing area of interest to help aid in the management of patients with chronic congestive heart failure. The utility of remote hemodynamic monitoring has not previously been investigated with a ventricular assist device population. We present two cases of patients with ventricular assist devices in which we employed remote hemodynamic monitoring data to aid in patient management.


Sign in / Sign up

Export Citation Format

Share Document